Ocular assessment of patients treated with tamoxifen

Beck, M.; Mills, P.V.

Cancer Treatment Reports 63(11-12): 1833-1834

1979


ISSN/ISBN: 0361-5960
PMID: 526917
Document Number: 151964
Tamoxifen is a specific estrogen antagonist used in the treatment of breast cancer. In a previous study, corneal and retinal changes were reported in four patients receiving high-dose tamoxifen therapy for greater than 1 year. Nineteen patients treated with tamoxifen for periods of 3 months to 4 years at normal dose levels have been studied and no ocular changes attributable to the drug were observed.

Document emailed within 1 workday
Secure & encrypted payments